Page 1

Consolidated Investment Analysis for Medtronic Inc.  Medtronic, Inc. (NYSE: MDT)  Company Description  Medtronic, Inc. (Medtronic) is a medical technology company. The Company is engaged in research, design, manufacture and sale of products to alleviate pain, restore health and extend life. It manufactures and sells device-based medical therapies. It operates in seven segments: Cardiac Rhythm Disease Management, Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies and Physio-Control. Its primary customers include hospitals, clinics, third party healthcare providers, distributors and other institutions, including governmental healthcare programs and group purchasing organizations. In April 2010, the Company completed the acquisition of Invatec, S.p.A., a developer of medical technologies for the interventional treatment of cardiovascular disease. In November 2010, the Company acquired Osteotech.  Share Statistics  Symbol      MDT      EPS      2.90  Current Price    37.62      Market Cap    40.63B  52wk Range    30.80‐ 46.66    52wk Change    ‐12.96%  Avg Vol (3m)    7,074,720    P/E (ttm)    12.97  Financial Summary 

On November 23, 2010, Medtronic Inc reported 2nd quarter 2011 earnings of 0.82 per share. This result was in line with the consensus of the 27 analysts following the company and exceeded last year's 2nd quarter results by 6.49%. The next earnings announcement is expected on February 21, 2011. Medtronic Inc reported annual 2010 earnings of 3.23 per share on May 25, 2010. MDT had 2nd quarter 2011 revenues of 3.90bn. This bettered the 3.90bn consensus of the 25 analysts covering the company. This was 3.45% above the prior year's 2nd quarter results. MDT had revenues for the full year 2010 of 15.82bn. This was 8.34% above the prior year's results.


Analyst Consensus  Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 33 polled investment analysts. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Latest

7

7

18

1

0

0

4 weeks ago

5

7

18

1

0

0

2 months ago

6

7

17

1

0

0

3 months ago

6

7

17

0

0

0

Last year

9

6

14

0

0

0

The 25 analysts offering 12 month price targets for Medtronic Inc (MDT:NYQ) have a median target of 38.00, with a high estimate of 48.00 and a low estimate of 27.00. The median estimate represents a 1.60% increase from the last price of 37.40. Technical Analysis Chart 

   


Report Disclaimer  DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR  IN ONE OF OUR NEWSLETTERS. We are not registered as a securities broker‐dealer or an  investment advisor either within the U.S. Securities and Exchange Commission (the “SEC”) or  with any state securities regulatory authority. We are neither licensed nor qualified to provide  investment advice.  The information contained on our website or in any of our newsletters should be viewed as  commercial advertisement and is not intended to be investment advice. Any information found  on our website, or in any of our newsletters is not provided to any particular individual with a  view toward their individual circumstances. The information contained on our website, and in  any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions,  comments, and information free of charge exclusively to individuals who wish to receive them.  Our newsletter and website have been prepared for informational purposes only and are not  intended to be used as a complete source of information on any particular company. An  individual should never invest in the securities of any of the companies profiled based solely on  information contained in our report. Individuals should assume that all information contained  on our website or in one of our newsletters about profiled companies is not trustworthy unless  verified by their own independent research.  Any individual who chooses to invest in any securities should do so with caution. Investing in  securities is speculative and carries a high degree of risk; you may lose some or all of the money  that is invested. Always research your own investments and consult with a registered  investment adviser or licensed stock broker before investing.  This report is a service of Seo Freisin, Inc., a financial public relations firm that has been  compensated by the companies profiled. All direct and third party compensation received has  been disclosed on both, this newsletter, and on our website in accordance with section 17(b) of  the Securities Act of 1933. This compensation constitutes a conflict of interest as to our ability to   remain objective in our communication regarding the profiled companies. Seo Freisin, Inc.,  and/or its affiliates will hold, buy, and sell securities in the companies profiled. When  compensated in shares, all readers should be aware that it is our policy to liquidate   all shares immediately. We reserve the right to buy or sell the shares of any the companies  mentioned in any materials we produce at any time. This compensation constitutes a conflict of  interest as to our ability to remain objective in our communication regarding the profiled  companies.   ChartPoppers.com is a Web site wholly‐owned by Seo Freisin, Inc. Seo Freisin, Inc., has not been  compensated for any of the Companies mentioned in this report, we also do not own any shares  in the companies discussed in this report. 


Information contained in our report will contain “forward looking statements” as defined under  section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and  uncertainties outside of our control that could cause actual operations or results to differ  materially from those anticipated. Factors that could affect performance include, but are not  limited to, those factors that are discussed in each profiled company’s most recent reports or  registration statements filed with the SEC. You should consider these factors in evaluating the  forward looking statements included in the report and not place undue reliance upon such  statements.  We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the  information provided, including information regarding a profiled company’s plans or ability to  effect any planned or proposed actions. We have no first‐hand knowledge of any profiled  company’s operations and therefore cannot comment on their capabilities, intent, resources,  nor experience and we make no attempt to do so. Statistical information, dollar amounts, and  market size data was provided by the subject company and related sources which we believe to  be reliable.  To the fullest extent of the law, we will not be liable to any person or entity for the quality,  accuracy, completeness, reliability, or timeliness of the information provided in this report, or  for any direct, indirect, consequential, incidental, special or punitive damages that may arise out  of the use of information we provide to any person or entity (including, but not limited to, lost  profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or  incompleteness of this information).  We encourage you to invest carefully and read investment information available at the websites  of the SEC at http://www.sec.gov and FINRA at http://www.finra.org   

MDT  

MDT had 2nd quarter 2011 revenues of 3.90bn. This bettered the 3.90bn consensus of the 25 analysts covering the company. This was 3.45% abov...

Read more
Read more
Similar to
Popular now
Just for you